X
[{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Processa Pharmaceuticals To Move Forward With A PCS499 Phase 3 Trial After A Successful FDA Meeting","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Aposense","pharmaFlowCategory":"D","amount":"$127.5 million","upfrontCash":"Undisclosed","newsHeadline":"Processa Pharmaceuticals Has Entered into an Agreement with Aposense, to License in the Next Generation Irinotecan Drug","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Processa Pharmaceuticals","pharmaFlowCategory":"D","amount":"$103.1 million","upfrontCash":"$88.0 million","newsHeadline":"Processa Pharmaceutical Enters Licensing Agreement with Elion Oncology","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","amount":"$7.0 million","upfrontCash":"Undisclosed","newsHeadline":"Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Processa Pharmaceuticals Reports Positive Phase 1b Results with NGC-Cap in Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Processa Pharmaceuticals
Filters
Companies By Therapeutic Area
Details:
NGC-Cap is PCS6422 (eniluracil) administered in combination with capecitabine, a precursor of the cancer drug 5-FU. It is being evaluated for the treatment of gastrointestinal cancer.
Lead Product(s):
Eniluracil ,Capecitabine
Therapeutic Area: Oncology
Product Name: PCS6422
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 11, 2024
Details:
The net proceeds will be used to advance the development of PCS6422 (eniluracil) administered in combination with capecitabine, for the treatment of advanced, refractory gastrointestinal tract tumors.
Lead Product(s):
Eniluracil ,Capecitabine
Therapeutic Area: Oncology
Product Name: PCS6422
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
H.C. Wainwright & Co.
Deal Size: $7.0 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
February 01, 2024
Details:
NGC-Cap is PCS6422 (eniluracil) administered in combination with capecitabine, a precursor of the cancer drug 5-FU. It is being evaluated in phase 1 clinical trials for the treatment of gastrointestinal cancer.
Lead Product(s):
Eniluracil ,Capecitabine
Therapeutic Area: Oncology
Product Name: PCS6422
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 25, 2024
Details:
NGC-Cap combines the administration of PCS6422, the Company’s irreversible dihydropyrimidine dehydrogenase (DPD) enzyme inhibitor, with the administration of low doses of the commonly used chemotherapy capecitabine.
Lead Product(s):
Capecitabine ,Eniluracil
Therapeutic Area: Oncology
Product Name: NGC-Cap
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 19, 2023
Details:
PCS6422 is an oral drug to be administered with fluoropyrimidine cancer drugs to decrease the breakdown of the cancer drug to inactive metabolites or metabolites that are known to cause unwanted side effects and to interfere with the anticancer activity.
Lead Product(s):
Eniluracil ,Capecitabine
Therapeutic Area: Oncology
Product Name: PCS6422
Highest Development Status: Phase I
Product Type: Small molecule
Recipient:
Elion Oncology
Deal Size: $103.1 million
Upfront Cash: $88.0 million
Deal Type: Licensing Agreement
August 27, 2020
Details:
Under this Condition Precedent License Agreement, Aposense will grant Processa a worldwide, royalty-bearing right and license, including the right to sublicense, their next generation irinotecan cancer drug, ATT-11T, upon satisfaction of the set conditions.
Lead Product(s):
Irinotecan Hydrochloride
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Undisclosed
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Aposense
Deal Size: $127.5 million
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
June 01, 2020
Details:
With input from the FDA, Processa will be designing and conducting a Phase 3 trial to evaluate the ability of PCS499 to completely close ulcers in patients with NL.
Lead Product(s):
PCS499
Therapeutic Area: Dermatology
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 30, 2020